Subject(s)
Hypereosinophilic Syndrome/diagnosis , Hypereosinophilic Syndrome/drug therapy , Hypertrophy, Left Ventricular/diagnosis , Hypertrophy, Left Ventricular/drug therapy , Oncogene Proteins, Fusion/biosynthesis , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Receptor, Platelet-Derived Growth Factor alpha/biosynthesis , mRNA Cleavage and Polyadenylation Factors/biosynthesis , Adult , Benzamides , Chronic Disease , Humans , Hypereosinophilic Syndrome/genetics , Hypertrophy, Left Ventricular/genetics , Imatinib Mesylate , Male , Treatment OutcomeABSTRACT
In-stent restenosis of a previously atherosclerotic renal artery stenosis initially treated with endovascular stenting may progress to subtotal occlusion and loss of renal function. The clinical course of an acute occlusion is mainly acute oligo-anuric renal failure. Therefore, rapid diagnosis and treatment are critical for renal survival. Even after successful endovascular treatment, a close clinical monitoring, and optimized medical treatment including sufficient blood pressure control, lipid lowering and platelet inhibition, is mandatory to prolong the preservation of renal function. Here we present a patient with subtotal in-stent stenosis affecting the left solitary kidney and recovery of renal function 24 h after the revascularization procedure.
